|
摘要：
|
|
摘要：目的 探讨中药疏肝解郁方治疗慢性乙型肝炎（chronic hepatitis B，CHB）伴抑郁的临床疗效。
方法 选取2016年1月至2018年6月深圳市第三人民医院收治的90例CHB伴抑郁患者为研究对象，采用
随机数字表法分为治疗组和对照组，每组45例。对照组患者给予恩替卡韦片治疗，治疗组患者给予
恩替卡韦片联合中药疏肝解郁方治疗，疗程均为8周。比较治疗前后两组患者的丙氨酸氨基转移酶
（alanine aminotransferase，ALT）、天门冬氨酸氨基转移酶（aspartate aminotransferase，AST）、汉
密顿抑郁量表（Hamilton depression scale，HAMD）评分、皮质醇（cortisol，Cor）、白细胞介素-2
（interleukin-2，IL-2）、自然杀伤（natural killer，NK）细胞及主要中医证候评分，并比较两组患者
的治疗总有效率。结果 治疗前两组患者的ALT、AST、HAMD评分、Cor、IL-2、NK细胞及主要中医
证候评分差异均无统计学意义（P ＞ 0.05）；治疗后两组患者ALT、AST、HAMD评分、Cor、各项中
医证候评分较治疗前显著降低（P ＜ 0.01），IL-2和NK细胞水平显著升高（P ＜ 0.05）；治疗组上述
各项指标治疗前后差值显著大于对照组（P ＜ 0.05）。对照组总有效率为73.3%（33/45）；治疗组总
有效率为93.3%（42/45），差异有统计学意义（z = 6.238，P = 0.013）。结论 疏肝解郁方可减轻患者
抑郁症状，改善肝功能，纠正免疫功能紊乱，治疗CHB合并抑郁疗效显著。
|
|
Abstract: Objective To investigate the clinical efficacy of Shugan Jieyu prescription on chronic hepatitis B
patients with depression. Methods Total of 90 chronic hepatitis B patients with depression in the Third People’s
Hospital of Shenzhen from January 2016 to June 2018 were selected and divided into treatment group and
control group according to random digital table method, 45 cases in each group. Patients in control group were
treated with entecavir tablets and patients in treatment group were treated with entecavir tablets combined
with traditional Chinese medicine Shugan Jieyu prescription, all patients were treated for 8 weeks. The levels
of alanine aminotransferase (ALT), aspartate aminotransferase (AST), Hamilton depression scale (HAMD)
score, cortisol (Cor) and interleukin-2 (IL-2), natural killer (NK) cell contents and the main traditional Chinese
medicine (TCM) syndrome scores of the two groups were compared before and after treatment, and the total
effective rate of the two groups was compared. Results Before treatment, there were no statistically significant
differences in ALT, AST, HAMD scores, the contents of NK cell and the main TCM syndrome scores between
the two groups (P ＞ 0.05). After treatment, the ALT, AST, HAMD score, Cor and syndrome score of patients in
two groups were significantly lower than those before treatment, while the levels of IL-2 and NK cells increased
significantly (P ＜ 0.05). The above indexes of patients in treatment group before and after treatment were
significantly higher than those in control group (P ＜ 0.05). The total effective rate was 73.3% (33/45) in control
group and 93.3% (42/45) in treatment group, the difference was statistically significant (z = 6.238, P = 0.013).
Conclusion Shugan Jieyu prescription can relieve depressive symptoms, improve liver function, correct immune
dysfunction, and has a significant effect on chronic hepatitis B with depression.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|